Nan Fung Trinity HK Ltd. Makes New $4.96 Million Investment in Xenon Pharmaceuticals Inc. $XENE

Nan Fung Trinity HK Ltd. purchased a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 158,605 shares of the biopharmaceutical company’s stock, valued at approximately $4,964,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Xenon Pharmaceuticals by 15.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,964 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 403 shares in the last quarter. Mutual of America Capital Management LLC bought a new position in Xenon Pharmaceuticals in the 1st quarter valued at approximately $1,636,000. Natixis Advisors LLC raised its holdings in Xenon Pharmaceuticals by 1.9% in the 1st quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company’s stock valued at $806,000 after buying an additional 456 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Xenon Pharmaceuticals by 439.0% during the 1st quarter. Bank of New York Mellon Corp now owns 251,147 shares of the biopharmaceutical company’s stock worth $8,426,000 after buying an additional 204,550 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ grew its holdings in Xenon Pharmaceuticals by 17.5% during the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 47,457 shares of the biopharmaceutical company’s stock worth $1,592,000 after acquiring an additional 7,081 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Up 3.9%

NASDAQ:XENE opened at $39.92 on Wednesday. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $44.60. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -11.25 and a beta of 1.10. The firm has a fifty day simple moving average of $39.39 and a two-hundred day simple moving average of $35.47.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.01. During the same quarter in the prior year, the firm posted ($0.81) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Ian Mortimer sold 25,000 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $40.16, for a total value of $1,004,000.00. Following the completion of the transaction, the chief executive officer owned 31,302 shares in the company, valued at $1,257,088.32. This trade represents a 44.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.07% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 14th. Bloom Burton raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, October 7th. Chardan Capital reaffirmed a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, October 7th. Wedbush increased their price target on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, August 12th. Finally, William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $53.70.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.